JP2016526909A - Ｆｃ含有ポリペプチドの安定化 - Google Patents

Ｆｃ含有ポリペプチドの安定化 Download PDF

Info

Publication number
JP2016526909A
JP2016526909A JP2016531860A JP2016531860A JP2016526909A JP 2016526909 A JP2016526909 A JP 2016526909A JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016526909 A JP2016526909 A JP 2016526909A
Authority
JP
Japan
Prior art keywords
polypeptide
region
antibody
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016531860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526909A5 (OSRAM
Inventor
カナン，グナセーカラン
ラバリー，ジェニファー
ジェイコブセン，フレデリック・ダブリュ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2016526909A publication Critical patent/JP2016526909A/ja
Publication of JP2016526909A5 publication Critical patent/JP2016526909A5/ja
Priority to JP2020160475A priority Critical patent/JP7344858B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
JP2016531860A 2013-07-31 2014-07-30 Ｆｃ含有ポリペプチドの安定化 Pending JP2016526909A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020160475A JP7344858B2 (ja) 2013-07-31 2020-09-25 Ｆｃ含有ポリペプチドの安定化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
US61/860,800 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020160475A Division JP7344858B2 (ja) 2013-07-31 2020-09-25 Ｆｃ含有ポリペプチドの安定化

Publications (2)

Publication Number Publication Date
JP2016526909A true JP2016526909A (ja) 2016-09-08
JP2016526909A5 JP2016526909A5 (OSRAM) 2017-09-07

Family

ID=52432568

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016531860A Pending JP2016526909A (ja) 2013-07-31 2014-07-30 Ｆｃ含有ポリペプチドの安定化
JP2020160475A Active JP7344858B2 (ja) 2013-07-31 2020-09-25 Ｆｃ含有ポリペプチドの安定化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020160475A Active JP7344858B2 (ja) 2013-07-31 2020-09-25 Ｆｃ含有ポリペプチドの安定化

Country Status (15)

Country Link
US (3) US20160193295A1 (OSRAM)
EP (1) EP3027647A4 (OSRAM)
JP (2) JP2016526909A (OSRAM)
KR (3) KR20160034404A (OSRAM)
CN (1) CN105658664A (OSRAM)
AU (3) AU2014296215A1 (OSRAM)
BR (1) BR112016002219A2 (OSRAM)
CA (1) CA2919076C (OSRAM)
CL (1) CL2016000232A1 (OSRAM)
EA (1) EA035319B1 (OSRAM)
HK (1) HK1224203A1 (OSRAM)
IL (1) IL243690B (OSRAM)
MX (2) MX2016001165A (OSRAM)
SG (1) SG11201600734YA (OSRAM)
WO (1) WO2015017548A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530283A (ja) * 2017-07-07 2020-10-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規治療学的酵素融合タンパク質及びその用途
JP2021507705A (ja) * 2017-12-22 2021-02-25 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
JP7084881B2 (ja) * 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
JP7250677B2 (ja) * 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2018144784A1 (en) * 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
CN111182915A (zh) * 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
UA129980C2 (uk) 2018-08-03 2025-10-01 Емджен Рісерч (Мюнік) Ґмбг Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
PE20221416A1 (es) * 2019-09-18 2022-09-20 Novartis Ag Proteinas de fusion nkg2d y sus usos
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
MY209909A (en) * 2019-12-11 2025-08-11 Lg Chemical Ltd Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
MX2022014636A (es) 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CA3189721A1 (en) * 2020-08-21 2022-02-24 Ajou University Industry-Academic Cooperation Foundation Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (c.gamma.1) and epsilon constant reggion (c.epsilon.2-4) are fused, and use thereof
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
US12161692B2 (en) 2020-11-02 2024-12-10 Attralus, Inc. SAP FC fusion proteins and methods of use
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
US20240350588A1 (en) * 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN119080948B (zh) * 2023-04-17 2025-05-27 北京康乐卫士生物技术股份有限公司 带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523971A (ja) * 1997-05-02 2001-11-27 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2819038C (en) * 2010-12-06 2023-10-17 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523971A (ja) * 1997-05-02 2001-11-27 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530283A (ja) * 2017-07-07 2020-10-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規治療学的酵素融合タンパク質及びその用途
JP7697784B2 (ja) 2017-07-07 2025-06-24 ハンミ ファーマシューティカル カンパニー リミテッド 新規治療学的酵素融合タンパク質及びその用途
JP2021507705A (ja) * 2017-12-22 2021-02-25 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
JP7403455B2 (ja) 2017-12-22 2023-12-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
US12435328B2 (en) 2017-12-22 2025-10-07 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体

Also Published As

Publication number Publication date
WO2015017548A3 (en) 2015-11-05
IL243690A0 (en) 2016-04-21
JP2021019598A (ja) 2021-02-18
AU2020200329A1 (en) 2020-02-06
CA2919076A1 (en) 2015-02-05
US20250325631A1 (en) 2025-10-23
MX2016001165A (es) 2016-06-29
IL243690B (en) 2022-09-01
EA201690299A1 (ru) 2016-11-30
KR20250152665A (ko) 2025-10-23
US20160193295A1 (en) 2016-07-07
US20190192628A1 (en) 2019-06-27
AU2014296215A1 (en) 2016-02-11
MX2022008013A (es) 2022-07-27
WO2015017548A2 (en) 2015-02-05
BR112016002219A2 (pt) 2017-09-12
CA2919076C (en) 2024-01-30
KR20230141929A (ko) 2023-10-10
CN105658664A (zh) 2016-06-08
AU2022201204B2 (en) 2025-01-02
EP3027647A4 (en) 2017-01-04
SG11201600734YA (en) 2016-02-26
CL2016000232A1 (es) 2016-09-02
AU2022201204A1 (en) 2022-03-17
KR20160034404A (ko) 2016-03-29
HK1224203A1 (zh) 2017-08-18
EA035319B1 (ru) 2020-05-27
EP3027647A2 (en) 2016-06-08
JP7344858B2 (ja) 2023-09-14

Similar Documents

Publication Publication Date Title
JP7344858B2 (ja) Ｆｃ含有ポリペプチドの安定化
JP6329585B2 (ja) 単量体抗体Ｆｃ
JP7178342B2 (ja) アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子
EP3576789B1 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
JP2018162253A (ja) 遺伝子操作された免疫グロブリン重鎖−軽鎖対およびその使用
US20230235024A1 (en) Fc-Containing Molecules Exhibiting Predictable, Consistent, and Reproducible Glycoform Profiles
TW201100543A (en) Tri-or tetraspecific antibodies
JP2023027107A (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
CN119431599A (zh) 工程改造铰链区以驱动抗体二聚化
EP2966085A1 (en) Antibody IgG1 with a modified heavy chain constant region
HK40037872A (en) Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526